Report: CPOE market poised for growth

Laura Pedulli | | Health Exec | Precision Medicine

The computerized physician order entry (CPOE) market is expected to grow 6.5 percent, or from $938.4 million in 2013 to $1.28 billion in 2018, according to a report from Texas-based research firm MicroMarket Monitor.

Government initiatives are spurring a number of technological advancements in CPOE and extensive usage of CPOE systems by emergency healthcare service providers, hospitals, nurses and office-based physicians also is fueling market growth, according to the report.

Key market players include Cerner, Allscripts, Epic, McKesson, GE Healthcare, Athenahealth, Meditech, Zynx Health and Emdeon.

North America is the largest CPOE systems market, which is poised to grow from $552.9 million in 2013 to $771.2 million in 2018. Federal government initiatives and high healthcare costs are factors in this growth. However, the cost and time involved in the installation of CPOE systems are major factors restraining market growth, according to the report.

Europe is the second largest CPOE systems market, which is expected to grow from $218.7 million in 2013 to $292.4 million in 2018. Increasing European government investments in such technology contributes to the demand. However, the Eurozone debt crisis, and the cost and time involved in the installation of the CPOE systems are the major factors preventing growth.

Asia is expected to be the fastest growing CPOE market, which is anticipated to grow from $117.3 million in 2013 to $163.9 million in 2018. However, the complexity of CPOE systems and poor hardware infrastructures are the most significant factors restraining growth.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.